- Creative BioMolecules, Ontogeny, Reprogenesis merge
- Ortho terminates BMP-7 program with Curis
- Curis and Wyeth end hedgehog pathway deal for neurology
- Biogen gets Creative BioMolecules' OP-1 protein for $123mm
- Curis, Elan establish JV to develop hedgehog agonists; ended
- Stryker buys manufacturing of OP-1 from Creative
- Curis, Genentech sign second pathway deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.